Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2023 - 2025)

Historic Goodwill & Intangibles for ARS Pharmaceuticals (SPRY) over the last 3 years, with Q3 2025 value amounting to $14.7 million.

  • ARS Pharmaceuticals' Goodwill & Intangibles rose 9638.67% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 9638.67%. This contributed to the annual value of $7.4 million for FY2024, which is 109465.15% up from last year.
  • ARS Pharmaceuticals' Goodwill & Intangibles amounted to $14.7 million in Q3 2025, which was up 9638.67% from $13.0 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Goodwill & Intangibles peaked at $14.7 million during Q3 2025, and registered a low of $446000.0 during Q2 2024.
  • Over the past 3 years, ARS Pharmaceuticals' median Goodwill & Intangibles value was $7.3 million (recorded in 2024), while the average stood at $6.4 million.
  • Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Goodwill & Intangibles was 280852.02% (2025), while the steepest drop was 9638.67% (2025).
  • Over the past 3 years, ARS Pharmaceuticals' Goodwill & Intangibles (Quarter) stood at $617000.0 in 2023, then skyrocketed by 1094.65% to $7.4 million in 2024, then skyrocketed by 99.82% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $13.0 million for Q2 2025, and $7.2 million during Q1 2025.